Abnormal activation of Mer kinase has been implicated in the oncogenesis of many human cancers including acute lymphoblastic and myeloid leukemia, non-small cell lung cancer, and glioblastoma. We have discovered a new family of small molecule Mer inhibitors, pyrazolopyrimidine sulfonamides, that potently inhibit the kinase activity of Mer. Importantly, these compounds do not demonstrate significant hERG activity in the PatchXpress assay. Through structureeactivity relationship studies, 35 (UNC1062) was identified as a potent (IC 50 ¼ 1.1 nM) and selective Mer inhibitor. When applied to live tumor cells, UNC1062 inhibited Mer phosphorylation and colony formation in soft agar. Given the potential of Mer as a therapeutic target, UNC1062 is a promising candidate for further drug development.
Introduction
Mer belongs to the TAM (Tyro3, Axl, and Mer) family of receptor tyrosine kinases (RTKs) [1] . Under normal physiological conditions, Mer kinase promotes cell proliferation and survival, platelet aggregation, macrophage clearance of apoptotic cells, and cytokine release [2] . Abnormal activation of Mer has been implicated in the oncogenesis of many human cancers and is often associated with poor prognostic indicators [2, 3] . For example, Mer is ectopically expressed in both B-and T-cell acute lymphoblastic leukemias (ALL) [4] but not in normal mouse and human T-and B-lymphocytes at any stage of development. Similarly, Mer is expressed in the majority of acute myeloid leukemia (AML) cell lines and patient samples but not in normal bone marrow myeloid cells [5] . Finally, Mer is frequently overexpressed in solid tumors, including nonsmall cell lung cancer (NSCLC) cell lines [6] and patient samples, even though normal human bronchial epithelial (NHBE) cells and lung tissue adjacent to tumors do not express Mer protein [6] . Similar findings have been reported in other solid tumors, including glioblastoma (GBM) [3b,7] and metastatic melanoma [8] . This tumor specific expression pattern may confer a large therapeutic window e at least in these tumor types. Expression of a Mer transgene in hematopoietic cells leads to development of leukemia and/or lymphoma in mice [9] . In addition, when Mer is inhibited by sh-RNA knockdown in leukemia [4c], NSCLC [6] , or GBM cells [7a] , they are more susceptible to apoptotic death and exhibit reduced colony formation in soft agar. Moreover, in orthotropic ALL and AML xenograft mouse models, onset and progression of disease were delayed and survival was significantly increased in mice transplanted with Mer knockdown leukemia cell lines relative to mice transplanted with wild-type cell lines [4c,5] . Similarly, in an NSCLC xenograft mouse model growth of tumors is markedly slowed by Mer knockdown. In addition, the combination of standard cytotoxic chemotherapies with shRNA-mediated Mer knockdown results in synergistic tumor cell killing. Taken together, these data demonstrate important roles of Mer for oncogenesis and antiapoptotic activity in multiple tumor types. Therefore, Mer provides a novel therapeutic target for the treatment of ALL, AML, NSCLC, and other Mer-related diseases. Consequently, Mer inhibitors are expected to both mediate direct anti-tumor, proapoptotic effects and augment chemosensitivity in combination with standard therapies.
Few small molecule Mer inhibitors have been reported [10] , among them compound 1 (UNC569) (Fig. 1) is the most promising one demonstrating inhibition of Mer at sub-nanomolar concentrations [11] . However, UNC569 has undesirable activity toward the human ether-a-go-go-related gene potassium channel (hERG) in the conventional PatchXpress assay (EC 50 ¼ 1.7 mM) [12] . Inhibition of hERG could lead to long QT syndrome and sudden death and is the reason for the withdrawal of several FDA-approved drugs [13] . In an effort to decrease the hERG activity of UNC569 through analog synthesis, we discovered that sulfonamide 2 ( Fig. 1 ) had similar activity against Mer kinase with better physical properties. Consequently, compound 2 is a better starting point than UNC569 to develop potent Mer inhibitors as potential therapeutics. Herein we report the structureeactivity relationship (SAR) of a series of compounds related to 2 on inhibiting the TAM family kinases and the discovery of potent Mer inhibitors with minimal hERG activity and excellent cellular activity.
Synthesis
The synthetic routes to sulfonamide analogs (Scheme 1) are similar to what we have previously developed for the synthesis of analogs of UNC569 [11] . Briefly, 3-chlorobenzoperoxoic acid (m-CPBA) oxidation of the known compound 3 [14] followed by the displacement of the methyl sulfinyl/sulfonyl group by amines provided the intermediate 4, which was subsequently alkylated at the N1 position of the pyrazole ring to yield 5. Suzuki coupling between 5 and a boronic acid provided the final product 6.
Results and discussion
Most hERG inhibitors contain a basic amine group and we thus speculate that the hERG activity of 1 may be due to the presence of a primary amine (NH 2 ) at the R 2 position (Table 1) . Consequently, we
first synthesized a focused library of compounds with different R 2 groups while keeping R 1 fixed as N-methylbenzenesulfonamide.
Inhibition of Mer kinase activity by analogs was tested at the K m for ATP using a microfluidic capillary electrophoresis (MCE) assay [15] in which phosphorylated and unphosphorylated substrate peptides were separated and analyzed using a LabChip EZ Reader. For comparison, inhibition of other members in the TAM RTK family, Tyro3 and Axl, was also measured. As shown in Table 1 , when the Fig. 1 . The structures and enzymatic activities of 1 and 2.
Scheme 1. The synthetic routes for sulfonamide analogs. NH 2 group at the R 2 position (2) was replaced by a hydroxyl (OH) group (7), the activity of the analog 7 was decreased 5-fold. Increasing the length of the linker between the pyrazole ring and the cyclohexyl group also decreased the activity of compounds (8, 9 vs 2). In contrast, when the length of the linker was shortened and R 2 was replaced with a trans-4-hydroxycyclohexyl group, the corresponding analog 10 had enhanced activity compared to the parent 7. More specifically, the IC 50 value was changed from 18 nM for 7 to 2.4 nM for 10, suggesting that the conformational rigidity and the size of R 2 was important for Mer inhibition. Consistent with this notion, analogs 12 and 13, which featured open chain versions of cyclohexanol at the R 2 position, had decreased Mer inhibition.
Using a tetrahydropyran to replace the 4-hydroxycyclohexyl group provided analogs that were less active (14, 15 and 16) . Furthermore, a cyclohexyl group alone at the R 2 position resulted in a 28-fold weaker inhibitor 17, which further confirmed our previous observation: a hydrogen bond between the polar substituent at the R 2 position with the carbonyl of Arg727 of Mer protein was important [11] . The configuration of the hydroxyl group was not critical, as the cis-analog 11 had similar activity as trans-10.
We also tested the activity of the synthetic analogs against Axl and Tyro3 to monitor their selectivity for TAM family members and develop a pan-TAM SAR. In general, these analogs showed modest selectivity within the TAM family and are generally less potent against Axl and Tyro3. In addition, to test our hypothesis regarding on the cause of the hERG activity, compounds 2 and 10 were characterized in the hERG binding assay. Indeed, 10 had no hERG activity in the PatchXpress assay while 2 was active with an EC 50 of 3.2 mM. Removal of the primary amine at R 2 position eliminated the binding of our compounds to the hERG channel.
Next, the SAR at the R 1 site was explored (Table 2 ). In general, these analogs are very potent against Mer (at sub-nanomolar concentrations) and have good selectivity for Mer over Axl (>16 fold) and Tyro3 (>9 fold). A reversed sulfonamide functional group (18), sulfonic acid (19) and unsubstituted sulfonamide (20) at the R 1 site were tolerated. When one of the acidic hydrogens in sulfonamide was substituted with a small alkyl group such as propyl (21) or iso-propyl (22), the activity of the analogs remained the same. In contrast, a cycloalkyl group such as cyclopropyl (23), cyclopentyl (24) and cyclohexyl (25) at this position yielded a more active analog. A tetrahydropyran (26) or 4-piperidinylmethyl (28) group was also well tolerated at this position while a para-fluorophenyl ring (27) was less suitable. Interestingly, 29, the precursor of 28 with a Boc protection group at piperidinyl nitrogen, was equally potent, which could be explained by the fact that the R 1 position was exposed to solvents as observed in the X-ray structure of UNC569 complexed with Mer [11] . To further confirm this explanation, we introduced a large side chain at this position and found that the corresponding derivative 30 was still active. Finally, when the acidic hydrogen on the sulfonamide functional group was replaced by a variety of alkyl groups, the activity and TAM RTKselectivity of the resulting analogs 31e36 were maintained [16] . Compared to UNC569, 35 (UNC1062) had improved selectivity and activity against Mer relative to other TAM family RTKs (78-fold selectivity over Axl and 54-fold over Tyro3). Morrison tight-binding inhibition studies revealed that UNC1062 had a K i of 0.33 nM against Mer [17] . These outstanding inhibitory profiles of UNC1062 prompted us to further investigate its activity in intact cell systems.
The ability of UNC1062 to inhibit Mer auto-phosphorylation in different cell lines was first tested. Briefly, human pre-B leukemia 697 cells were grown in suspension and treated with various concentrations of UNC1062 for 1 h prior to addition of a phosphatase inhibitor to stabilize phospho-Mer. Mer protein was immunoprecipitated from lysates and phospho-Mer and total Mer proteins were detected by western blot. In this cell-based assay, the IC 50 value for inhibition of phospho-Mer by UNC1062 was 6.4 nM (Fig. 2) . In comparison, the IC 50 of UNC569 in the same assay was 141 nM [11] , suggesting that UNC1062 was significantly more potent than UNC569 both with purified Mer kinase and in intact cells.
To determine if UNC1062 inhibits Mer phosphorylation in adherent cells, similar studies were performed using a human, adherent, pediatric rhabdoid brain tumor cell line (BT-12) and two NSCLC cell lines (A549 and Colo699). Inhibition of Mer phosphorylation was evident in cells when the concentration of UNC1062 was above 300 nM (Fig. 3A) . Similarly, phosphorylation of Mer was stably inhibited over 72 h of culture in A549 and Colo699 NSCLC cells treated with 250 nM or 500 nM UNC1062 (Fig. 3B) . Thus, while solid tumor cells require significantly higher concentrations of UNC1062 compared to non-adherent leukemia cells, possibly as a result of decreased exposure across adherent cell membranes, treatment with UNC1062 at sub-micromolar concentrations was sufficient to inhibit Mer phosphorylation in adherent cell lines.
To determine if UNC1062 can mediate functional anti-tumor effects, BT-12, A549, and Colo699 cells were cultured in soft agar overlaid with medium containing UNC1062 or vehicle only. Treatment with 1.0 mM UNC1062 was sufficient to completely abrogate growth of BT-12 rhabdoid tumor colonies in soft agar (Fig. 4A) . Similarly, treatment with UNC1062 inhibited colony formation in both A549 and Colo699 NSCLC cultures (Fig. 4B) . Moreover, inhibition of colony formation in long-term soft agar assays and inhibition of Mer phosphorylation in short-term assays occurred at similar concentrations of UNC1062 in these cell lines, consistent with a causal relationship.
Conclusions
In summary, we have identified and synthesized a new family of small molecule Mer inhibitors, pyrazolopyrimidine sulfonamides, which potently inhibit the kinase activity of Mer. Importantly, this new generation of inhibitors do not show significant hERG activity in the PatchXpress assay. Through structureeactivity relationship studies, 35 (UNC1062) was identified as both a potent (K i ¼ 0.33 nM) and selective Mer inhibitor. When applied to live cells, UNC1062 inhibited Mer phosphorylation and colony formation in soft agar. These results provide the first evidence of anti-tumor activity mediated by a member of this novel class of inhibitors, thus further validate Mer as a drug target for cancer.
Experimental

General
Microwave reaction was carried out using a Discover-S reactor with a vertically-focused IR external temperature sensor and an Explorer 72 autosampler. The dynamic mode was used to set up the desired temperature and hold time with the following fixed parameters: Prestirring, 1 min; Pressure, 200 psi; Power, 200 W; PowerMax, off; stirring, high. Flash chromatography was carried out on pre-packed silica gel disposable columns. Analytical thinlayer chromatography (TLC) was performed with silica gel 60 F 254 , 0.25 mm pre-coated TLC plates. TLC plates were visualized using UV 254 or phosphomolybdic acid with charring. All 1 H NMR spectra were obtained with a 400 MHz spectrometer and 13 C NMR spectra were obtained with a 100 MHz spectrometer. Preparative HPLC was performed with the UV detection at 220 or 254 nm. LCe MS was performed with the UV detection at 220 nm, 254 nm, and 280 nm, and a single quadrupole mass spectrometer using electrospray ionization (ESI) source. High-resolution (positive ion) mass spectra (HRMS) were acquired using a LCMS-TOF mass spectrometer.
Synthesis
To a mixture of 3-bromo-6-(methylthio)-1H-pyrazolo[3,4-d] pyrimidine (24.5 g, 100 mmol) in THF (100 mL) was added metachloroperoxybenzoic acid (33.7 g, 77%, 150 mmol) in portions at room temperature. The white mixture was stirred for 2 h and transferred into a THF (50 mL) solution of n-butylamine (49.4 mL, 500 mmol) at 0 C. The resulting solution was heated at 60 C for 2.0 h. After removal of the solvent under reduced pressure, MeOH was added and the mixture was filtered. The white solid was 
A mixture of 4 (0.054 g, 0.20 mmol), K 2 CO 3 (0.11 g, 0.8 mmol), DMF (2.0 mL), and tert-butyl (trans-4-(chloromethyl)cyclohexyl) carbamate (0.062 g, 0.25 mmol) in a 10 mL microwave tube was heated under microwave irradiation at 150 C for 10 min. After cooling to room temperature, (4-(N-methylsulfamoyl) phenyl)boronic acid (0.065 g, 0.30 mmol), Pd(PPh 3 ) 4 (0.023 g, 0.020 mmol), and H 2 O (1.0 mL) were added sequentially. The resulting mixture was stirred at room temperature for 1.0 min and then heated under microwave irradiation at 150 C for 15 min. After cooling to room temperature, the mixture was quenched with H 2 O and extracted with EtOAc (3Â). The combined organic layer was dried (Na 2 SO 4 ) and concentrated. The residue was purified by an ISCO silica gel column to provide tert-
carbamate as a white solid. This white solid was dissolved in CH 2 Cl 2 (2.0 mL), then was added TFA (0.5 mL) at room temperature. The resulting solution was stirred for 1.0 h and was concentrated. The residue was purified by prep-HPLC to provide the title compound 2 as a white solid (0.053 g, 48% over 3 steps).
General procedure A: A mixture of 4 (0.054 g, 0.20 mmol), K 2 CO 3 (0.11 g, 0.8 mmol), DMF (2.0 mL), and tert-butyl((trans-4-(chloromethyl)cyclohexyl)oxy)dimethylsilane (0.066 g, 0.25 mmol) in a 10 mL microwave tube was heated under microwave irradiation at 150 C for 10 min. After the reaction mixture was cooled to room temperature, (4-(N-methylsulfamoyl)phenyl)boronic acid (0.065 g, 0.30 mmol), Pd(PPh 3 ) 4 (0.023 g, 0.020 mmol), and H 2 O (1.0 mL) were added sequentially. The mixture was stirred at room temperature for 1.0 min and then heated under microwave irradiation at 150 C for 15 min. After cooling to room temperature, the mixture was quenched with H 2 O and extracted with EtOAc (3Â). The combined organic layers were dried (Na 2 SO 4 ) and concentrated. The residue was purified by an ISCO silica gel column to provide
methylbenzenesulfonamide as a white solid. This white solid was dissolved in THF (2.0 mL) and was added TBAF (1.0 M in THF, 1 mL) at room temperature. The resulting solution was refluxed for 2.0 h and was concentrated. The residue was purified by prep-HPLC to provide the title compound 7 (0.040 g, 44% over 3 steps) as a white solid. 1 
The title compound 8 (0.040 g, 42%) was prepared according to general procedure A from tert-butyl((trans-4-(2-chloroethyl) cyclohexyl)oxy)dimethylsilane (0.069 g, 0.25 mmol) as a white solid. with medium containing UNC1062 or vehicle only. Medium and UNC1062 were refreshed twice weekly. Colonies were stained and counted. Representative plates are shown. B) A549 and Colo699 NSCLC cells were cultured in 0.35% soft agar overlaid with medium containing UNC1062 or vehicle only. Medium and UNC1062 were refreshed 3 times per week. Colonies were stained and counted. Mean values AE SEM derived from 3 independent experiments are shown. *Statistically significant results were determined using the student's paired t test (*p < 0.02, **p < 0.001 relative to vehicle only). 
The title compound 9 (0.055 g, 56%) was prepared according to general procedure B from tert-butyl((trans-4-(3-chloropropyl) cyclohexyl)oxy)dimethylsilane (0.069 g, 0.25 mmol) as a white solid. were added sequentially. The resulting mixture was stirred at room temperature for 1.0 min and then heated under microwave irradiation at 150 C for 15 min. After cooling to room temperature, the mixture was quenched with H 2 O and extracted with EtOAc (3Â). The combined organic layer was dried (Na 2 SO 4 ) and concentrated. The residue was purified by prep-HPLC to provide the title compounds 10 (0.011 g, 13% over 3 steps) and 11 (0.020 g, 23% over 3 steps) as white solids. 
General procedure C: A mixture of 4 (0.054 g, 0.20 mmol), K 2 CO 3 (0.11 g, 0.8 mmol), DMF (2.0 mL), and 2-bromoethanol (0.038 g, 0.30 mmol) in a 10 mL microwave tube was heated under microwave irradiation at 150 C for 10 min. After cooling to room temperature, (4-(N-methylsulfamoyl)phenyl)boronic acid (0.065 g, 0.30 mmol), Pd(PPh 3 ) 4 (0.023 g, 0.020 mmol), and H 2 O (1.0 mL) were added sequentially. The resulting mixture was stirred at room temperature for 1.0 min and then heated under microwave irradiation at 150 C for 15 min. After cooling to room temperature, the mixture was quenched with H 2 O and extracted with EtOAc (3Â). The combined organic layers were dried (Na 2 SO 4 ) and concentrated. The residue was purified by an ISCO silica gel column to provide the title compound 12 (0.044 g, 57%) as a white solid. 
General procedure D: A mixture of 4 (0.054 g, 0.20 mmol), K 2 CO 3 (0.11 g, 0.8 mmol), DMF (2.0 mL), and 4-chlorotetrahydro-2H-pyran (0.072 g, 0.60 mmol) in a 10 mL microwave tube was heated under microwave irradiation at 200 C for 30 min. After cooling to room temperature, (4-(N-methylsulfamoyl)phenyl) boronic acid (0.065 g, 0.30 mmol), Pd(PPh 3 ) 4 (0.023 g, 0.020 mmol), and H 2 O (1.0 mL) were added sequentially. The resulting mixture was stirred at room temperature for 1.0 min and then heated under microwave irradiation at 150 C for 15 min. After cooling to room temperature, the mixture was quenched with H 2 O and extracted with EtOAc (3Â). The combined organic layers were dried (Na 2 SO 4 ) and concentrated. The combined organic layer was dried (Na 2 SO 4 ) and concentrated under reduced pressure. The residue was purified by an ISCO silica gel column to provide the title compound 14 as a white solid (0.052 g, 61% over 2 steps). 
N-Methyl-4-(6-(butylamino)-1-((tetrahydro-2H-pyran-4-yl) methyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzenesulfonamide (15)
The title compound 15 (0.062 g, 70% over 2 steps) was prepared according to general procedure C from 4-(bromomethyl)tetrahydro-2H-pyran (0.045 g, 0.25 mmol) as a white solid. 1 
N-Methyl-4-(6-(butylamino)-1-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzenesulfonamide (16)
The title compound 16 (0.058 g, 63% over 2 steps) was prepared according to general procedure C from 4-(2-bromoethyl) tetrahydro-2H-pyran (0.048 g, 0.25 mmol) as a white solid. 1 
trans-4-(3-Bromo-6-(butylamino)-1H-pyrazolo[3,4-d] pyrimidin-1-yl)cyclohexanol
To a solution of 4 (2.70 g, 10 mmol) and cis-4-chlorocyclohexanol (4.04 g, 30 mmol) in DMF (50 mL) was added K 2 CO 3 (5.52 g, 40 mmol). The reaction mixture was heated at 150 C for overnight, quenched with water at room temperature and extracted with EtOAc (3Â). The combined organic layer was dried (Na 2 SO 4 ) and concentrated. The residue was purified by an ISCO silica gel column to afford the title compound (1.83 g, 52%) as a white solid. 161.6, 155.0, 153.4, 119.1, 110.3, 107.7, 68.3, 55.5, 34.6, 30.9, 29.8, 20.0, 14.1 
trans-N-(4-(6-(Butylamino)-1-(4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)methanesulfonamide (18)
The title compound 18 (0.008 g, 18%) was prepared according to general procedure B from (4-(methylsulfonamido)phenyl)boronic acid (0.033 g, 0.15 mmol) as a white solid. 1 
4-(1-(trans-4-Hydroxycyclohexyl)-6-(butylamino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzenesulfonic acid (19)
General procedure E: A mixture of trans-4-(3-bromo-6-(butylamino)-1H-pyrazolo [3,4-d] pyrimidin-1-yl)cyclohexanol (0.055 g, 0.15 mmol), K 3 PO 4 (0.063 g, 0.30 mmol), 4-boronobenzenesulfonic acid (0.045 g, 0.225 mmol), Pd(PPh 3 ) 4 (0.017 g, 0.015 mmol), dioxane (2.0 mL) and H 2 O (0.5 mL) in a 10 mL microwave tube was heated under microwave irradiation at 150 C for 10 min. After cooling to room temperature, the mixture was quenched with H 2 O and extracted with EtOAc (3Â). The combined organic layer was dried (Na 2 SO 4 ) and concentrated. The residue was filtered through a plug of Celite and then purified by prep-HPLC to afford the title compound 19 (0.027 g, 30%) as a white solid. 1 
4-(6-(Butylamino)-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclopropylbenzenesulfonamide (23)
The title compound 23 (0.003 g, 4%) was prepared according to general procedure E from (4-(N-cyclopropylsulfamoyl)phenyl) boronic acid (0.090 g, 0.375 mmol) as a white solid. 
trans-4-(6-(
The title compound 24 (0.015 g, 10%) was prepared according to general procedure B from (4-(N-cyclopentylsulfamoyl)phenyl) boronic acid (0.121 g, 0.45 mmol) as a white solid. 1 
The title compound 25 (0.015 g, 11%) was prepared according to general procedure B from (4-(N-cyclohexylsulfamoyl)phenyl) boronic acid (0.110 g, 0.39 mmol) as a white solid. 1 
The title compound 26 (0.016 g, 10%) was prepared according to general procedure B from (4-(N-(tetrahydro-2H-pyran-4-yl)sulfamoyl)phenyl)boronic acid (0.128 g, 0.45 mmol) as a white solid. 1 
The title compound 27 (0.009 g, 6%) was prepared according to general procedure B from 4- (N-(4-fluorophenyl) 
trans-tert-Butyl 4-((4-(6-(butylamino
The title compound 29 (0.011 g, 9%) was prepared according to general procedure B from (4-(N-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)sulfamoyl)phenyl)boronic acid (0.119 g, 0.30 mmol, 1.5 equiv) as a white solid. 1 
trans-4-(6-(
A mixture of 29 (20 mg, 0.03 mmol) and TFA (2.3 mL) in dichloromethane (4.7 mL) was stirred at room temperature for 2.0 h, then diluted with dichloromethane (20 mL) and washed with a saturated aqueous NaHCO 3 solution, water and brine. The organic layer was dried (Na 2 SO 4 ) and concentrated to afford the title compound 28 (12.7 mg, 75%) as a white solid. 1 
The title compound 31 (0.052 g, 74%) was prepared according to general procedure E from (4-(N,N-dimethylsulfamoyl) 
The title compound 32 (0.058 g, 76%) was prepared according to general procedure E from ((4-(N-(tert-butyl) 
The title compound 34 (0.020 g, 27%) was prepared according to general procedure E from (4-(pyrrolidin-1-ylsulfonyl)phenyl) boronic acid (0.096 g, 0.375 mmol) as a white solid. The title compound 35 (0.063 g, 82%) was prepared according to general procedure E from 4- ((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) d 160.6, 155.2, 154.0, 140.6, 136.9, 133.7, 128.3, 127.0, 105.1, 68.0, 65.3, 55.0, 45.9, 40.3, 34.2, 30.6, 29.4, 19.6, 13.7 
Microfluidic capillary electrophoresis (MCE) assay
Activity assays were performed in a 384 well, polypropylene microplate with a final volume of 50 mL in 50 mM Hepes, pH 7.4 containing 10 mM MgCl 2 , 1.0 mM DTT, 0.01% Triton X-100, 0.1% bovine serum albumin (BSA), using 1.0 mM fluorescent substrate (Table 3 ) and ATP at K m for each enzyme (Table 3 ). All reactions were terminated by addition of 20 mL of 70 mM EDTA. Phosphorylated and unphosphorylated substrate peptides (Table 3) were separated following a 180 min incubation on a LabChip EZ Reader equipped with a 12-sipper chip in separation buffer supplemented with 1 Â CR-8 and analyzed using EZ Reader software.
Morrison K i measurement
Inhibition of Mer kinase by UNC1062 was measured in the MCE assay using the Morrison tight-binding method [17b] . Reactions were performed in a 384 well, polypropylene microplate in a final volume of 80 mL in 50 mM Hepes, pH 7.4 containing 10 mM MgCl 2 , 1.0 mM DTT, 0.01% Triton X-100, 0.1% bovine serum albumin (BSA), and 5.0 mM ATP. Compounds were tested in 20 dilution (1.5 fold) dose curves spanning a concentration range of 60e0.027 nM, 2.0 nM Mer, 1.0 mM peptide substrate, and 5.0 mM ATP, final. To 40 mL of enzyme (4 nM Mer), 8.0 mL of compound in 10% DMSO was added and allowed to incubate for 10 min followed by addition of 32 mL of substrate mix (containing 2.5 mM peptide substrate and 12.5 mM ATP).
Kinetic reads were taken from 7.0 to 209 min, 12 reads total, on an EZ Reader, using upstream voltage ¼ À2250 V, downstream voltage ¼ À500 V and pressure ¼ À1.0 psi (sip time 0.2 s, buffer 30 s). The steady-state velocity was analyzed by linear regression of the peptide as percent-conversion/min, and a plot of nM compound (UNC1062) vs. velocity was fit to the Morison equation using GraphPad Prism The next day, the medium is removed and replaced with 30 mL/well of assay buffer containing membrane potential dye (Molecular Devices) (the lyophilized dye is reconstituted with 15 mL of assay buffer). After a 15 min incubation at 37 C, 30 mL/well of 2Â dilutions of terfenadine (a known HERG blocker used as a reference compound) or test compound (final assay concentration ranging 
Cell based assays for Mer kinase inhibition
697, BT-12, A549, or Colo699 cells were cultured in the presence of UNC1062 or vehicle only for 1.0 h (697, BT-12) or 72 h (A549, Colo699). Pervanadate solution was prepared fresh by combining 20 mM sodium orthovanadate in 0.9Â PBS in a 1:1 ratio with 0.3% (w/w) hydrogen peroxide in PBS for 15e20 min at room temperature. Cultures were treated with 120 mM pervanadate prior to collection for preparation of whole cell lysates, immunoprecipitation of Mer, and analysis by western blot. 697, A549, and Colo699 cells were treated with pervanadate for 3.0, 5.0, and 1.0 min respectively. Cell lysates were prepared in 50 mM HEPES pH 7.5, 150 mM NaCl, 10 mM EDTA, 10% glycerol, and 1% Triton X-100, supplemented with protease inhibitors (Roche Molecular Biochemicals, #11836153001). Mer protein was immunoprecipitated with a monoclonal anti-Mer antibody (R&D Systems, #MAB8912) and Protein G agarose beads (InVitrogen). Phospho-Mer was detected by western blot using a polyclonal anti-phospho-Mer antibody raised against a peptide derived from the tri-phosphorylated activation loop of Mer. Nitrocellulose membranes were stripped and total Mer protein was detected using a second anti-Mer antibody (Epitomics Inc., #1633-1). For 697 cells, relative phosphorylated and total Mer protein levels were determined by densitometry and IC 50 values were determined by non-linear regression.
Confluent BT-12 cultures were treated with pervanadate for 15 min. Cell lysates were prepared in 20 mM HEPES pH 7.5, 500 mM NaCl, 5.0 mM EDTA, 10% glycerol, and 1% Triton X-100, supplemented with protease inhibitors (10 mg/mL leupeptin, 10 mg/mL phenylmethylsulfonyl fluoride, and 20 mg/ml aprotinin) and phosphatase inhibitors (50 mM sodium fluoride and 1.0 mM sodium orthovanadate) and Mer protein was immunoprecipitated using a custom polyclonal rabbit anti-Mer antisera raised against a peptide derived from the N-terminus of Mer and Protein A agarose beads (Santa Cruz Biotechnology). Phosphotyrosine-containing proteins were detected by western blot with a monoclonal HRP-conjugated anti-phosphotyrosine antibody (Santa Cruz Biotechnology, #sc-508). Antibodies were stripped from membranes and total Mer levels were determined using a custom polyclonal rabbit anti-Mer raised against a peptide derived from the catalytic domain of Mer.
Soft agar colony formation assays
BT-12 cells (10,000 cells) were cultured in 2.0 mL of 0.35% soft agar containing 0.5Â RPMI medium, 7.5% FBS, and the indicated concentrations of UNC1062 or DMSO vehicle only and overlaid with 0.5 mL of 1Â RPMI medium containing 15% FBS and UNC1062 or DMSO vehicle only. Medium and UNC1062 or vehicle were refreshed 2 times per week. Colonies were stained with thiazolyl blue tetrazolium bromide (Sigma Aldrich, #M5655) and counted after 3 weeks.
A549 or Colo699 cells (15,000 cells) were cultured in 1.5 mL of 0.35% soft agar containing 1Â RPMI medium and 10% FBS and overlaid with 2.0 mL of 1Â RPMI medium containing 10% FBS and the indicated concentrations of UNC1062 or DMSO vehicle only. Medium and UNC1062 or vehicle were refreshed 3 times per week. Colonies were stained with nitrotetrazolium blue chloride (Sigma Aldrich, #N6876) and counted after 2 weeks.
